Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Join SI Premium – FREE
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.42), $0.28 worse than the analyst estimate of ($1.14).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
- Applied Materials (AMAT) Tops Q3 EPS by 10c, Offers Guidance
- Cadrenal Therapeutics, Inc. (CVKD) Tops Q2 EPS by 27c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
